Safety and outcome of rtPA in acute ischemic stroke in patients with active cancer: case-control study.

CONCLUSION: Severe haemorrhagic complications, potentiated by rtPA, carry increased risk of morbidity and mortality. Nevertheless, selected cancer patients with AIS may benefit from rtPA treatment. Active cancer should not be considered an absolute contraindication to rtPA use. Risk of complications and life expectancy should be assessed when making this decision. PMID: 28650062 [PubMed - in process] (Source: Revista de Neurologia)

from MedWorm via o.lakala70 on Inoreader http://ift.tt/2s3k07K
via IFTTT